Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology. Our lead asset, upifitamab rilsodotin (XMT-1536, UpRi), is a first-in-class Dolaflexin ADC in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Our next clinical stage ADC, XMT-1592, a Dolasynthen ADC-targeting NaPi2b expressing tumors entered the clinic in May 2020.
| ADC Program | Target | Indication | Platform | Discovery | Preclinical | P1 | P1 | P2 | P3 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical | |||||||||||
| upifitamab rilsodotin (UpRi)* |
NaPi2b |
Ovarian Cancer | Dolaflexin | ||||||||
| XMT-1536* | NaPi2b |
NSCLC Adenocarcinoma | Dolaflexin | ||||||||
| Preclinical | |||||||||||
| XMT-1592* | NaPi2b |
Ovarian Cancer NSCLC Adenocarcinoma | Dolasynthen | ||||||||
| Discovery | |||||||||||
| XMT-1660 | B7-H4 |
Multiple Solid Tumors | Dolasynthen | ||||||||
| XMT-2056 | Undisclosed |
Undisclosed | Immunosynthen | ||||||||
| Multiple Programs | Undisclosed |
Undisclosed | Immunosynthen | ||||||||
| Multiple Programs | Undisclosed |
Undisclosed | Dolaflexin or Dolasynthen | ||||||||
| Platform Collaborations | |||||||||||
| Multiple | Multiple |
Undisclosed | Dolaflexin | ||||||||
| ASN004 | 5T4 |
Undisclosed | Dolaflexin | ||||||||
| Drug | Indication | Stage | ||
| Clinical | upifitamab rilsodotin (UpRi)* |
NaPi2b |
Ovarian Cancer | Dolaflexin | P1 |
| XMT-1536* | NaPi2b |
NSCLC Adenocarcinoma | Dolaflexin | Preclinical |
| Preclinical | XMT-1592* | NaPi2b |
Ovarian Cancer NSCLC Adenocarcinoma | Dolasynthen | Preclinical |
| Discovery | XMT-1660 | B7-H4 |
Multiple Solid Tumors | Dolasynthen | Discovery |
| XMT-2056 | Undisclosed |
Undisclosed | Immunosynthen | Discovery |
| Multiple Programs | Undisclosed |
Undisclosed | Immunosynthen | Discovery |
| Multiple Programs | Undisclosed |
Undisclosed | Dolaflexin or Dolasynthen | |
| Platform Collaborations | Multiple | Multiple |
Undisclosed | Dolaflexin | Discovery |
| ASN004 | 5T4 |
Undisclosed | Dolaflexin | Discovery |
| ADC Program | Target | Indication | Platform | Phase |
|---|---|---|---|---|
| XMT-1536* | upifitamab rilsodotin (UpRi)* | Ovarian Cancer | Dolaflexin | P2 Pivotal Study |
| XMT-1536* | NaPi2b | NSCLC Adenocarcinoma | Dolaflexin | P1 Proof of Concept |
| XMT-1592* | NaPi2b | Ovarian Cancer NSCLC Adenocarcinoma | Dolasynthen | P1 Dose Escalation |
| XMT-1660 | B7-H4 | Multiple Solid Tumors | Dolasynthen | Preclinical |
| XMT-2056 | Undisclosed | Undisclosed | Immunosynthen | Preclinical |
| Multiple Programs | Undisclosed | Undisclosed | Immunosynthen | Preclinical |
| Multiple Programs | Undisclosed | Undisclosed | Dolaflexin or Dolasynthen | Discovery |
Multiple
|
Multiple | Undisclosed | Dolaflexin | Preclinical |
ASN004 |
5T4 | Undisclosed | Dolaflexin | Preclinical |
*NaPi2b antibody used in UpRi (formerly XMT-1536) and XMT-1592 is in-licensed from Recepta Biopharma. Recepta has rights to commercialize UpRi and XMT-1592 in Brazil.